Skip to main navigation
Alpine Immune Sciences Alpine Immune Sciences

Main navigation

  • About Us
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
    • Contact Us
  • Pipeline & Programs
    • Pipeline
    • Acazicolcept (ALPN-101)
    • ALPN-202
    • ALPN-303
    • Science & Platform
    • Scientific Publications
  • Clinical Trials
  • Investors
    • Stock Information
    • Analyst Coverage
    • News Release
    • Events & Presentations
    • SEC Filings
    • Governance
  • Careers
  • No menu assigned!

News Releases

Investor Relations - Horizontal

news releases  |  events  |  sec filings  |  governance  | 

board of directors  |  management team  |  documents  |  committee composition  | 

  • May 12, 2022
    Summary ToggleAlpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results
    SEATTLE --(BUSINESS WIRE)--May 12, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for
    Read More
  • May 3, 2022
    Summary ToggleAlpine Immune Sciences Announces Participation in May Investor Conferences
    SEATTLE --(BUSINESS WIRE)--May 3, 2022-- Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate
    Read More
  • April 12, 2022
    Summary ToggleAACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts
    - In dose escalation across a range of dose regimens, tumor volume reduction was observed in 23% of evaluable participants despite heavily pretreated, advanced solid malignancies - - Monotherapy expansion cohorts with multiple tumor types are planned - NEW ORLEANS --(BUSINESS WIRE)--Apr.
    Read More
  • April 5, 2022
    Summary ToggleAlpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event
    - AACR Investor Event time change to 6:30 p.m. ET - - 21st Annual Needham Virtual Healthcare Conference Presentation April 13 th at 1:30 p.m. ET - SEATTLE --(BUSINESS WIRE)--Apr. 5, 2022-- Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on
    Read More
  • April 4, 2022
    Summary ToggleAlpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications
    - Novel approach to CD28 to enhance activation of T cells and anti-tumor activity - - Crystallography demonstrates critical interaction between davoceticept’s CD80 domain and PD-L1 - - Data further encourage ongoing davoceticept development, including NEON-1 monotherapy and NEON-2 pembrolizumab
    Read More
  • March 30, 2022
    Summary ToggleAlpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting
    - Alpine to hold Investor Event on Tuesday, April 12 th at 6:00pm ET - SEATTLE --(BUSINESS WIRE)--Mar. 30, 2022-- Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory
    Read More
  • March 17, 2022
    Summary ToggleAlpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
    - Execution across three clinical-stage programs and addition of $176 million in committed cash in 2021 from partnerships and financing to further advance pipeline - - Davoceticept monotherapy dose escalation data to be presented at 2022 AACR Annual Meeting - - ALPN-303 phase 1 ongoing; data
    Read More
  • March 8, 2022
    Summary ToggleAlpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting
    - NEON-1 Data Selected for Minisymposium Oral Presentation - SEATTLE --(BUSINESS WIRE)--Mar. 8, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today
    Read More
  • March 7, 2022
    Summary ToggleAlpine Immune Sciences Reports FDA Partial Clinical Hold on NEON-2 Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
    -NEON-1 Study of ALPN-202 as a Monotherapy is Unaffected- SEATTLE --(BUSINESS WIRE)--Mar. 7, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today
    Read More
  • March 1, 2022
    Summary ToggleAlpine Immune Sciences Announces Participation in March Investor Conferences
    SEATTLE --(BUSINESS WIRE)--Mar. 1, 2022-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate
    Read More

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last
Displaying 1 - 10 of 132 results

Toolkit

  • Contact Us
  • Email Alerts
  • RSS Feeds
  • Print Page
  • Email Page

Contact

188 East Blaine Street
Suite 200
Seattle, WA
98102
206-788-4545

Sitemap

  • About Us
  • Pipelines & Programs
  • Clinical Trials
  • Investors
  • Careers
  • Contact Us
  • Legal

Twitter

@AlpineImmuneSci

LATEST TWEETS

Tweets by @AlpineImmuneSci

© 2022 Alpine Immune Sciences. All Rights Reserved, Alpine Immune Sciences Inc.

Investor Relations - Horizontal

  • News Releases
  • Events
  • SEC Filings
  • Governance
    • Board of Directors
    • Management Team
    • Documents
    • Committee Composition